

Recent patent applications in microRNAs

Patent #	Subject	Assignee(s)	Inventor(s)	Priority application date	Publication date
US 20050227934	An isolated DNA or RNA molecule comprising at least ten contiguous bases having a sequence in a pancreatic islet microRNA comprising any one of 20 defined sequences; useful for treating diabetes.	Poy MN; Stoffel M; Tuschl TH; Rockefeller University (New York)	Poy MN, Stoffel M, Tuschl TH	4/13/2004	10/13/2005
WO 200592393	A cell growth inhibitor comprising a microRNA complementary to a transcription product of the WT1 gene; useful for treating cancer.	Sugiyama H	Oji Y, Sugiyama H	3/29/2004	10/6/2005
US 20050221293	A novel, isolated, single-stranded DNA virus microRNA molecule comprising moieties having contiguous bases bonded to backbone units; useful for controlling gene expression in organisms.	Pfeffer S, Tuschl TH	Pfeffer S, Tuschl TH	8/24/2004	10/6/2005
US 20050182005	An isolated single stranded anti-microRNA molecule comprising a minimum of 10 moieties and a maximum of 50 moieties on a molecular backbone; useful for inhibiting micro ribonucleoprotein particle (microRNP) activity in a cell, and for modulating gene expression.	Landthaler M; Meister G; Pfeffer S; Tuschl TH; Rockefeller University (New York)	Landthaler M, Meister G, Pfeffer S, Tuschl TH	2/13/2004	8/18/2005
US 20050144669	A composition comprising an isolated nucleotide sequence able to be transcribed by a plant cell into precursor microRNA that is cleavable by the plant cell to produce microRNA substantially complementary to at least a portion of an mRNA sequence encoding a gene.	Rice University (Houston, TX, USA); Whitehead Institute for Biomedical Research (Cambridge, MA, USA)	Bartel B, Bartel DP, Reinhart BJ, Rhoades MW, Weinstein EG	7/1/2003	6/30/2005
WO 200554494	A method for inhibiting RNA silencing of a gene (e.g., for treating cancer), comprising contacting a cell or organism containing short interfering RNA or microRNA that directs RNA silencing of a gene, with an RNA silencing-inhibitory agent.	Hutvagner G; Zamore PD University of Massachusetts (Boston)	Hutvagner G, Zamore PD	2/10/2004	6/16/2005
WO 200542705	A method for identifying a siRNA nucleotide sequence to target an mRNA sequence, comprising comparing a database of mRNA sequences with a siRNA nucleotide sequence to determine the complementarity of mRNA sequences to a nucleotide sequence of the siRNA nucleotide. The method includes identifying or designing a microRNA nucleotide sequence that does not function as a siRNA nucleotide sequence.	University of Pennsylvania (Philadelphia)	Kiriakidou M, Mourelatos Z, Sharma A	10/22/2003	5/12/2005
WO 200540419	An oligonucleotide array comprising a surface and oligonucleotides, where at least one oligonucleotide has at least one modified sugar moiety; useful in genomics applications, particularly for detecting small RNAs, and for prognosing or diagnosing diseases such as cancer.	Novartis AG; Novartis Forschungsstiftung (Basel); Novartis Pharma GmbH (Vienna)	Filipowicz W, Hall J, Kolb F, Lange JB, Wanke C, Weiler J	10/14/2003	5/6/2005
FR 2861086	An <i>in vitro</i> method for inducing the activity of an interfering RNA in cells; makes possible reliable functional analysis of genes, particularly human genes, and the nucleic acid that encodes interfering RNA can be used as a pharmaceutical.	Centre National de la Recherche Scientifique (Paris)	Ait SAS, Benkirane M, Harel BA, Ait-Si-Ali S, Harel-Bellan A	10/20/2003	4/22/2005

Source: Thomson Scientific Search Service (formerly Derwent). The status of each application is slightly different from country to country. For further details, contact Thomson Scientific, 1725 Duke Street, Suite 250, Alexandria, Virginia 22314, USA. Tel: 1 (800) DERWENT (<http://www.thomson.com/scientific>).

